Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 05/28/15

Joel Morris, PhD

Joel Morris, PhD: Branch Chief

Chief

Drug Synthesis and Chemistry Branch

Joel Morris serves as Chief of the Drug Synthesis & Chemistry Branch (DSCB), Developmental Therapeutics Program at the National Cancer Institute. Prior to his current appointment in 2010, Dr. Morris spent a significant tenure in the pharmaceutical industry as a Senior Scientist with The Upjohn Company/Pharmacia & Upjohn, and as a Research Fellow with Pfizer. In this capacity, he led and was a member of research teams responsible for the discovery of advanced clinical (selective erbB2 inhibitor CP-724714, HIV-reverse transcriptase inhibitor PNU-142721) and preclinical candidates for the treatment of cancer, HIV-infection and AIDS, bacterial infections, restenosis, and thrombosis. He has extensive experience with the development and implementation of strategies for the prosecution of early exploratory chemistry programs, including hit-to-lead and fragment-based approaches. Dr. Morris is heavily invested in the utilization of modern medicinal chemistry strategies and techniques as well as advanced data visualization and computational chemistry tools to understand trends within data in order to design key derivatives for project progression. He is responsible for >50 publications and 20 patents, and has delivered >15 invited lectures. He obtained his Ph.D. in organic chemistry at Yale University with Professor Samuel Danishefsky and completed an NIH postdoctoral fellowship at CalTech with Professor David Evans.

About the Branch Chief

Joel Morris Joel Morris serves as Chief of the Drug Synthesis & Chemistry Branch (DSCB), Developmental Therapeutics Program at the National Cancer Institute. Prior to his current appointment in 2010, Dr. Morris spent a significant tenure in the pharmaceutical industry as a Senior Scientist with The Upjohn Company/Pharmacia & Upjohn, and as a Research Fellow with Pfizer. More…